

FOR THE FINANCIAL PERIOD ENDED 30 June 2019

ANNOUNCEMENT

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the fourth quarter ended 30 June 2019.

A PRESENTATION OF RESULTS

I CONDENSED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

	4th Quarter		Year-to-Date	
		-		
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	30.6.2019	30.6.2018	30.6.2019	30.6.2018
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Revenue	7,017	6,307	27,726	26,158
Cost of Sales	(5,524)	(4,458)	(20,084)	(17,015)
Gross profit	1,493	1,849	7,642	9,143
Other Income	26	76	367	200
Marketing and distribution	(211)	(289)	(1,104)	(1,698)
Finance cost	(231)	(297)	(960)	(671)
Administrative expenses	(2,377)	(2,878)	(9,461)	(11,351)
Profit / (loss) before tax	(1,300)	(1,539)	(3,516)	(4,377)
Income tax expenses	(43)	94	(322)	(156)
Profit / (loss), net of tax, representing total comprehensive income	(1,343)	(1,445)	(3,838)	(4,533)
Profit / (loss) attributable to:				
Owners of the parent	(1,343)	(1,445)	(3,838)	(4,533)
Net profit / (loss) for the period	(1,343)	(1,445)	(3,838)	(4,533)
Earnings / (Loss) per share (EPS) attributable				
to the equity holders of the Company (sen)				
Basic EPS	(1.30)	(1.40)	(3.71)	(4.38)
Diluted EPS	N/A	N/A	N/A	N/A

The unaudited condensed statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Notes:-

There is no income/expense in relation to other income including investment income, provision for/write-off of receivables, provision for/write-off of inventories, gain/loss on disposal of quoted or unquoted investments or properties, foreign exchange gain/loss, impairment of assets, gain/loss on derivatives, or exceptional items, except for as disclosed on the cashflow statement.

N/A - Not Applicable



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

A PRESENTATION OF RESULTS (cont.)

II CONDENSED STATEMENT OF FINANCIAL POSITION

as at	30.6.2019 (RM'000)	30.6.2018 (RM'000)
ASSETS		
NON-CURRENT ASSETS		
Plant and equipment	14,314	13,232
Intangible assets	9,026	9,056
	23,340	22,288
CURRENT ASSETS		
Trade and other receivables	7,533	8,761
Inventories	1,584	2,160
Other current assets	9	6
Tax recoverable	203	248
Cash and bank balances	4,328	7,376
	13,657	18,551
TOTAL ASSETS	36,997	40,839
EQUITY AND LIABILITIES		
EQUITY ATTRIBUTABLE TO OWNERS OF THE PARENT		
Share capital	28,489	28,489
Accumulated losses	(12,557)	(8,719)
TOTAL EQUITY	15,932	19,770
NON-CURRENT LIABILITIES		
Deferred tax liability	736	685
Loans and borrowings	13,269	13,214
	14,005	13,899
CURRENT LIABILITIES		
Trade and other payables	3,060	2,806
Loans and borrowings	4,000	4,364
	7,060	7,170
TOTAL LIABILITIES	21,065	21,069
TOTAL EQUITY AND LIABILITIES	36,997	40,839
Net assets (RM'000)	15,932	19,770
Net assets per share attributable to equity holders of the Company (sen)	15.39	19.10

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

A PRESENTATION OF RESULTS (cont.)

III CONDENSED STATEMENT OF CHANGES IN EQUITY

		K N	on-Distributabl	le 	Distributable
	Equity, Total	Share Capital	Share Premium	Other reserve	Retained Earnings / (Accumulated Losses)
for the financial year ended 30 June 2018	(RM'000)	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Opening balance at 1 July 2017 Total comprehensive income / (loss)	24,304 (4,534)	10,351	18,138 -	(1,682)	(2,503) (4,534)
Transfer to accumulated losses	-	-	-	1,682	(1,682)
Effect of the Companies Act 2016	-	18,138	(18,138)	-	-
Closing balance at 30 June 2018	19,770	28,489	-	-	(8,719)
for the financial year ended 30 June 2019	(RM'000)	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Opening balance at 1 July 2018	19,770	28,489	-	-	(8,719)
Total comprehensive income / (loss)	(3,838)	-	-	-	(3,838)
Closing balance at 30 June 2019	15,932	28,489	-		(12,557)

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

A PRESENTATION OF RESULTS (cont.)

IV CONDENSED STATEMENT OF CASH FLOWS

	Year-t	o-Date
		Previous Year
for the financial period ended	30.6.2019	30.6.2018
	(RM'000)	(RM'000)
Cash flows from operating activities		
Profit / (loss) before tax	(3,516)	(4,377)
Adjustments for:	(3,310)	(1,377)
Impairment on trade receivables	_	262
Impairment on inventories	514	94
Amortisation of intangible assets	30	768
Depreciation of plant and equipment	1,120	940
Plant and equipment written off	13	7
Interest income	(160)	(149)
Interest expenses	960	671
Operating profit / (loss) before working capital changes	(1,039)	(1,784)
(Increase) / decrease in receivables	1,225	1,582
(Increase) / decrease in inventories	62	(251)
(Decrease) / increase in inventories	254	(5,008)
Cash (used in) / generated from operations	502	(5,461)
Tax refund/(paid)		(207)
	(226)	
Interest paid	(960)	(671)
Net cash (used in) / generated from operating activities	(684)	(6,339)
Cash flows from investing activities		
Interest received	160	149
Purchase of plant and equipment	(2,215)	(938)
Net cash (used in) / generated from investing activities	(2,055)	(789)
Cash flows from financing activities		
Proceeds from issuance of shares of a subsidiary company	-	7,000
Drawdown of term loan	4,500	8,000
Repayment of loans and borrowings	(4,305)	(2,427)
Net cash generated from / (used in) financing activities	195	12,573
Net (decrease) / increase in cash and cash equivalents	(2,544)	5,445
Cash and cash equivalents at beginning of the period	5,923	478
Cash and cash equivalents at beginning of the period	3,379	5,923
במשוו מווע במשוו בקעוועמובוונש מג בווע טו אבווטע		3,323

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS

B Explanatory Notes Pursuant to MFRS 134

i Basis of Preparation & Changes in Accounting Policies

These condensed consolidated interim financial statements have been prepared in accordance with MFRS 134 Interim Financial Reporting, and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

This report should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes. The significant accounting policies adopted in preparing these condensed consolidated interim financial statements are consistent with those of the audited financial statements for the financial year ended 30 June 2018.

Details of standards, amendments to published standards and interpretations to existing standards that are applicable to the Group with effect from 1 January 2018 or later are provided in the notes to the audited financial statements of the Group for the financial year ended 30 June 2018.

ii Auditors' Report on Preceding Annual Financial Statements

The audited financial statements for the financial year ended 30 June 2018 were not qualified.

iii Seasonal and Cyclical Factors

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

v Material Changes in Estimates

There were no material changes in the estimates that had effect(s) on the financial period.

vi Debt and Equity Securities

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

vii Dividends Paid

There were no dividends paid for the financial period.



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

B Explanatory Notes Pursuant to MFRS 134 (cont.)

viii Segmental Information

FRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Managing Director in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the forseeable future. Please refer to the financial statements presented in Part A of this announcement.

ix Valuation of Plant and Equipment

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

x Subsequent Events

There were no material events subsequent to the end of the current financial period under review that have not been reflected.

xi Changes in the Composition of the Group

There were no changes in the composition of the Group, including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations for the financial period to date.

xii Contingent Liabilities or Contingent Assets

There was no contingent liability or contingent asset arising since the last audited annual statement of financial position date as at 30 June 2018.

xiii Capital Commitments

There were no material capital commitments for the purchase of property, plant and equipment that were not provided for in the interim financial statements as at the end of the financial period.



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

B Explanatory Notes Pursuant to MFRS 134 (cont.)

xiv Related Party Transactions

Save as disclosed below, there were no significant related party transactions during the financial period to date:-

Significant Related Par	ty Transactions	4th Quarter		Year-to-Date	
		Current Year	Previous Year	Current Year	Previous Year
for the financial period er	nded	30.6.2019	30.6.2018	30.6.2019	30.6.2018
Related Party	Nature of Transaction	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Neuramatix, our ultimate holding company	Management fee payable to Neuramatix pursuant to Shared Services Agreement.	184	130	788	1,229
		184	130	788	1,229

xv Cash and Cash Equivalents

	Current Year	Previous Year	
as at	30.6.2019 (RM'000)	30.6.2018 (RM'000)	
Cash on hand and at banks	1,709	2,181	
Deposits with licensed banks	2,619	5,195	
Less: Bank overdraft	(949)	(1,453)	
	3,379	5,923	

xvi Inventories

Inventories written down amounted to RM514,558 during the financial period to date.



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements

These condensed consolidated interim financial statements, for the financial period ended 30 June 2019, have been prepared in accordance with Rule 9.22 and Appendix 9B of the Listing Requirements.

i Performance of the Group

Current Year 4th Quarter versus Previous Year 4th Quarter

A higher overall revenue (RM7 million for the fourth quarter ended 30 June 2019 as compared to RM6.3 million for the fourth quarter in the preceding year) was mainly contributed by higher pathology revenue.

Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM27.7 million, which represents an increase of RM1.5 million as compared to a revenue of RM26.2 million in the previous year-to-date.

The Group registered a loss before tax of RM3.5 million as compared to a loss before tax of RM4.4 million in the corresponding period of the preceding year. A lower loss was incurred mainly due to higher pathology revenue.

ii Comparison with Preceding Quarter's Results

The comparison of this quarter's results with the preceding quarter is set out below.

	Current Quarter	Preceding Quarter	Variance
for the financial period ended	30.6.2019 (RM'000)	31.3.2019 (RM'000)	(RM'000)
Revenue Profit / (loss) before tax	7,017 (1,300)	6,610 (929)	407 (371)

A higher revenue (RM7 million) was achieved in the current period as compared to the preceding quarter's revenue of RM6.6 million, contributed by higher pathology revenue.

iii Prospects of the Group

With the pathology revenue growing steadily, we remain focused on expanding our customer reach in the healthcare sector, differentiating our services and improving operational efficiency.



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

iv Variance from Profit Forecast

The Group did not publish any profit forecast.

v Taxation

Taxation	4th C	4th Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year	
for the financial period ended	30.6.2019 (RM'000)	30.6.2018 (RM'000)	30.6.2019 (RM'000)	30.6.2018 (RM'000)	
Malaysian income tax:					
Current period	43	(94)	322	156	
Prior period	-	-	-	-	
Total	43	(94)	322	156	

The above tax has arisen mainly due to the absence of group tax relief.

vi Status of Corporate Proposal

There is no corporate proposal announced but not completed as at the date of this announcement.

vii Loans and Borrowings

The Group's secured loans and borrowing are as follows:-

	30.6.2019 RM'000)	30.6.2018 (RM'000)
(R	RM'000)	(RM'000)
,		
Current		
Hire purchase and finance lease liabilities	-	91
Bank overdrafts	949	1,453
Term loans	3,051	2,820
	4,000	4,364
Non Current		
Term loans	6,269	6,214
Redeemable convertible cumulative preference shares ("RCCPS")	7,000	7,000
	13,269	13,214
Total Loans and borrowings	17,269	17,578



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

viii Material Litigations

As at the date of this announcement, there is no material litigation against the Group or taken by the Group.

ix Dividends

No dividends were declared during the current financial year under review.

x Trade receivables

The ageing analysis of the Group's trade receivables is as follows:-

	30.6.2019 (RM'000)
Not past due	2,125
Past due	
- less than 3 months	3,097
- 3 to 6 months	628
- over 6 months	1,214
	4,939
Impaired	(175)
	6,889

Receivables that are past due but not impaired

The Group believes that no impairment allowance is necessary in respect of these trade receivables. They are substantially companies with good collection track record and no recent history of default.



FOR THE FINANCIAL PERIOD ENDED 30 June 2019

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

xi EPS

a) **Basic EPS** Computed by dividing the profit / (loss), net of tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic EPS	4th Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	30.6.2019	30.6.2018	30.6.2019	30.6.2018
Profit / (loss), net of tax, attributable to owners of the parent (RM'000) Weighted average number of ordinary shares of RM0.10 each	((1,445)	(3,838)	(4,533)
issue ('000)	103,510	103,510	103,510	103,510
Basic EPS (sen)	(1.30)	(1.40)	(3.71)	(4.38)

b) **Diluted EPS** The Group does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.

xii Disclosure of Realised and Unrealised Profits / (Losses)

as at	30.6.2019 (RM'000)	30.6.2018 (RM'000)
Total accumulated losses:		
Realised	(14,105)	(10,267)
Unrealised	1,491	1,491
Total retained profit/(accumulated losses) of subsidiaries:		
Realised	46	46
Unrealised	11	11
Group accumulated losses	(12,557)	(8,719)

xiii Authorisation for Issue

The interim financial statements were authorised for issue by the Board of Directors of MGRC in accordance with a Resolution of the Directors dated 27 August 2019.